"Designing Growth Strategies is in our DNA"

Gastric Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug (Nivolumab, Pembrolizumab, Trastuzumab Deruxtecan, Trastuzumab, Ramucirumab, Zolbetuximab), By Product Type (Cytotoxic Chemotherapy, Immune Checkpoint Inhibitors), By Cancer Type (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma), By Age Group (Pediatric and Adults), By Type (Branded, Generic, Biosimilars), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), By Route of Administration (Oral, Parenteral), By Distribution Channel (Pharmacies, Drug Stores), and Regional Forecast, 2026-2034

Last Updated: July 03, 2026 | Format: PDF | Report ID: FBI117950

 

Buy Now

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Prevalence of Gastric Diseases, By Key Region/Countries
    2. Overview of Regulatory Scenario, By Key Regions/Countries
    3. New Product Launches, By Key Players
    4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
    5. Pipeline Analysis, By Key Players
  5. Global Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany 
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Merck & Co., Inc. 
      2. Bristol Myers Squibb
      3. Daiichi Sankyo Company, Limited
      4. Astellas Pharma Inc.
      5. F. Hoffmann-La Roche Ltd 
      6. AstraZeneca plc
      7. Eli Lilly and Company
      8. BeiGene 
      9. Taiho Oncology 
      10. Sanofi
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Prevalence of Gastric Diseases, By Key Region/Countries
    2. Overview of Regulatory Scenario, By Key Regions/Countries
    3. New Product Launches, By Key Players
    4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
    5. Pipeline Analysis, By Key Players
  5. Global Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany 
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Gastric Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Nivolumab
      2. Pembrolizumab
      3. Trastuzumab Deruxtecan
      4. Trastuzumab
      5. Ramucirumab
      6. Zolbetuximab
      7. Fluoropyrimidines
      8. Others 
    2. Market Analysis, Insights and Forecast – By Product Type        
      1. Cytotoxic Chemotherapy
      2. Immune Checkpoint Inhibitors
      3. HER2-Targeted Therapies
      4. VEGF/VEGFR-Targeted Therapies
      5. CLDN18.2-Targeted Therapies
      6. Nucleoside Analogue Combinations
      7. Others
    3. Market Analysis, Insights and Forecast – By Cancer Type          
      1. Gastric Adenocarcinoma
      2. Gastroesophageal Junction Adenocarcinoma
      3. Gastric Neuroendocrine Neoplasms
      4. Gastric Lymphoma
      5. Others
    4. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults 
    5. Market Analysis, Insights and Forecast – By Type
      1. Branded
      2. Generic
      3. Biosimilars
    6. Market Analysis, Insights and Forecast – By Therapy
      1. Targeted Therapy
      2. Immunotherapy
      3. Chemotherapy
      4. Others
    7. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    8. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
      4. Online Pharmacies
    9. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Merck & Co., Inc. 
      2. Bristol Myers Squibb
      3. Daiichi Sankyo Company, Limited
      4. Astellas Pharma Inc.
      5. F. Hoffmann-La Roche Ltd 
      6. AstraZeneca plc
      7. Eli Lilly and Company
      8. BeiGene 
      9. Taiho Oncology 
      10. Sanofi
Read Less

Figure 1:  Global Gastric Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 2:  Global Gastric Cancer Therapeutics Market Value Share (%), by Drug, 2025 & 2034

Figure 3:  Global Gastric Cancer Therapeutics Market Value Share (%), by Product Type, 2025 & 2034

Figure 4:  Global Gastric Cancer Therapeutics Market Value Share (%), by Cancer Type, 2025 & 2034

Figure 5:  Global Gastric Cancer Therapeutics Market Value Share (%), by Age Group, 2025 & 2034

Figure 6:  Global Gastric Cancer Therapeutics Market Value Share (%), by Type, 2025 & 2034

Figure 7:  Global Gastric Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034

Figure 8:  Global Gastric Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034

Figure 9:  Global Gastric Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034

Figure 10:  Global Gastric Cancer Therapeutics Market Value Share (%), by Region, 2025 & 2034

Figure 11:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Drug, 2025 & 2034

Figure 12:  North America Gastric Cancer Therapeutics Market Value Share (%), by Drug, 2025

Figure 13:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Product Type, 2025 & 2034

Figure 14:  North America Gastric Cancer Therapeutics Market Value Share (%), by Product Type, 2025

Figure 15:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Cancer Type 2025 & 2034

Figure 16:  North America Gastric Cancer Therapeutics Market Value Share (%), by Cancer Type 2025

Figure 17:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034

Figure 18:  North America Gastric Cancer Therapeutics Market Value Share (%), by Age Group, 2025

Figure 19:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Type, 2025 & 2034

Figure 20:  North America Gastric Cancer Therapeutics Market Value Share (%), by Type, 2025

Figure 21:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 22:  North America Gastric Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 23:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 24:  North America Gastric Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 25:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 26:  North America Gastric Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 27:  North America Gastric Cancer Therapeutics Market Value (USD billion), by Country, 2025 & 2034

Figure 28:  North America Gastric Cancer Therapeutics Market Value Share (%), by Country, 2025

Figure 29:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Drug, 2025 & 2034

Figure 30:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Drug, 2025

Figure 31:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Product Type, 2025 & 2034

Figure 32:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Product Type, 2025

Figure 33:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Cancer Type 2025 & 2034

Figure 34:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Cancer Type 2025

Figure 35:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034

Figure 36:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Age Group, 2025

Figure 37:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Type, 2025 & 2034

Figure 38:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Type, 2025

Figure 39:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 40:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 41:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 42:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 43:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 44:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 45:  Europe Gastric Cancer Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 46:  Europe Gastric Cancer Therapeutics Market Value Share (%), by Country/ Sub-region, 2025

Figure 47:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Drug, 2025 & 2034

Figure 48:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Drug, 2025

Figure 49:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Product Type, 2025 & 2034

Figure 50:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Product Type, 2025

Figure 51:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Cancer Type 2025 & 2034

Figure 52:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Cancer Type 2025

Figure 53:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034

Figure 54:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Age Group, 2025

Figure 55:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Type, 2025 & 2034

Figure 56:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Type, 2025

Figure 57:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 58:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 59:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 60:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 61:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 62:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 63:  Asia Pacific Gastric Cancer Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 64:  Asia Pacific Gastric Cancer Therapeutics Market Value Share (%), by Country/ Sub-region, 2025

Figure 65:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Drug, 2025 & 2034

Figure 66:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Drug, 2025

Figure 67:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Product Type, 2025 & 2034

Figure 68:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Product Type, 2025

Figure 69:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Cancer Type 2025 & 2034

Figure 70:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Cancer Type 2025

Figure 71:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034

Figure 72:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Age Group, 2025

Figure 73:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Type, 2025 & 2034

Figure 74:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Type, 2025

Figure 75:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 76:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 77:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 78:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 79:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 80:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 81:  Latin America Gastric Cancer Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 82:  Latin America Gastric Cancer Therapeutics Market Value Share (%), by Country/ Sub-region, 2025

Figure 83:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Drug, 2025 & 2034

Figure 84:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Drug, 2025

Figure 85:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Product Type, 2025 & 2034

Figure 86:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Product Type, 2025

Figure 87:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Cancer Type 2025 & 2034

Figure 88:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Cancer Type 2025

Figure 89:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Age Group, 2025 & 2034

Figure 90:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Age Group, 2025

Figure 91:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Type, 2025 & 2034

Figure 92:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Type, 2025

Figure 93:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 94:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 95:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 96:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 97:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 98:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 99:  Middle East & Africa Gastric Cancer Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 100:  Middle East & Africa Gastric Cancer Therapeutics Market Value Share (%), by Country/ Sub-region, 2025

Figure 101:  Global Gastric Cancer Therapeutics Market Share (%), by Company, 2025

Table 1:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 2:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Product Type, 2021–2034

Table 3:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Cancer Type 2021–2034

Table 4:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 5:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 6:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 7:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 8:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 9:  Global Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 10:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 11:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Product Type, 2021–2034

Table 12:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Cancer Type 2021–2034

Table 13:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 14:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 15:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 16:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 17:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 18:  North America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Country, 2021-2034

Table 19:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 20:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Product Type, 2021–2034

Table 21:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Cancer Type 2021–2034

Table 22:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 23:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 24:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 25:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 26:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 27:  Europe Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 28:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 29:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Product Type, 2021–2034

Table 30:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Cancer Type 2021–2034

Table 31:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 32:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 33:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 34:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 35:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 36:  Asia Pacific Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 37:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 38:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Product Type, 2021–2034

Table 39:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Cancer Type 2021–2034

Table 40:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 41:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 42:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 43:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 44:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 45:  Latin America Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 46:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 47:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Product Type, 2021–2034

Table 48:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Cancer Type 2021–2034

Table 49:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 50:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 51:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 52:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 53:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 54:  Middle East & Africa Gastric Cancer Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Gastric Cancer Therapeutics Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon
    Captcha refresh

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Customize Now
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports